Regeneron calls time on Eylea/nesvacumab combo
Regeneron says that a combination of Eylea and nesvacumab being co-developed with Bayer will not move into Phase III testing for two eye conditions following disappointing Phase II data.
Read More
Tag: DME
Merck buys into KalVista and its DME candidate
Shares in KalVista Pharmaceuticals have surged on news of a deal with Merck & Co potentially worth more than $750 million.
Read More
Roche bags Eleven’s experimental eye disease drug
Roche has snapped up rights to an experimental eye disease drug and technology from US biotech Eleven Biotherapeutics in a deal that be worth $270 million.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
